Skip to main content

Advertisement

SpringerLink
Log in

Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence?

  • Biomarkers of Heart Failure (WHW Tang, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

There has been a long history of the exploration into autoimmunity as a possible pathogenic factor of cardiovascular diseases from unknown cause represented by dilated cardiomyopathy (DCM). Autoantibodies (AAbs) have emerged either as humoral responses provoked by the release of “self-antigens” due to tissue damage or dysregulated humoral immunity itself. The pathogenic roles of some AAbs have been suggested by the findings from basic research using in vitro and in vivo disease models as well as clinical studies including immunoadsorption studies removing AAbs from patients with DCM. In this context, the importance of AAbs belonging to IgG3 subclass has also been implicated. In this review article, we summarize the findings accumulated to date regarding AAbs which have been considered to be involved in the pathology of DCM or pregnancy-related cardiovascular disease. Furthermore, we discuss the significance of AAbs as a possible cause of DCM and their potential roles as a novel therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85:1734–42.

    Article  CAS  PubMed  Google Scholar 

  2. Schultheiss HP, Schulze K, Schauer R, Witzenbichler B, Strauer BE. Antibody-mediated imbalance of myocardial energy metabolism. A causal factor of cardiac failure? Circ Res. 1995;76:64–72.

    Article  CAS  PubMed  Google Scholar 

  3. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res. 1989;64:97–103.

    Article  CAS  PubMed  Google Scholar 

  4. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res. 2001;88:578–86.

    Article  CAS  PubMed  Google Scholar 

  5. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Matsui S, Fu ML, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 1997;29:641–55.

    Article  CAS  PubMed  Google Scholar 

  7. Matsui S, Fu ML, Hayase M, Katsuda S, Yamaguchi N, Teraoka K, et al. Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001;38 Suppl 1:S43–9.

    Article  CAS  PubMed  Google Scholar 

  8. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;139:3630–6.

    CAS  PubMed  Google Scholar 

  9. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477–83.

    Article  CAS  PubMed  Google Scholar 

  10. Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177:8234–40.

    Article  CAS  PubMed  Google Scholar 

  11. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991;147:2141–7.

    CAS  PubMed  Google Scholar 

  12. Liao L, Sindhwani R, Rojkind M, Factor S, Leinwand L, Diamond B. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med. 1995;181:1123–31.

    Article  CAS  PubMed  Google Scholar 

  13. Caforio AL, Goldman JH, Baig MK, Haven AJ, Dalla Libera L, Keeling PJ, et al. Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart. 1997;77:62–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Lauer B, Schannwell M, Kuhl U, Strauer BE, Schultheiss HP. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol. 2000;35:11–8.

    Article  CAS  PubMed  Google Scholar 

  15. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol. 1995;27:397–406.

    Article  CAS  PubMed  Google Scholar 

  16. Mobini R, Magnusson Y, Wallukat G, Viguier M, Hjalmarson A, Hoebeke J. Probing the immunological properties of the extracellular domains of the human beta(1)-adrenoceptor. J Autoimmun. 1999;13:179–86.

    Article  CAS  PubMed  Google Scholar 

  17. Mobini R, Fu M, Wallukat G, Magnusson Y, Hjalmarson A, Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human beta1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma. 2000;19:135–42.

    Article  CAS  PubMed  Google Scholar 

  18. Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K. beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol. 2001;423:115–9.

    Article  CAS  PubMed  Google Scholar 

  19. Podlowski S, Luther HP, Morwinski R, Muller J, Wallukat G. Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation. 1998;98:2470–6.

    Article  CAS  PubMed  Google Scholar 

  20. Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, Lohse MJ. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol. 2000;36:1280–7.

    Article  CAS  PubMed  Google Scholar 

  21. Staudt Y, Mobini R, Fu M, Felix SB, Kuhn JP, Staudt A. Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol. 2003;466:1–6.

    Article  CAS  PubMed  Google Scholar 

  22. Christ T, Wettwer E, Dobrev D, Adolph E, Knaut M, Wallukat G, et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol. 2001;33:1515–25.

    Article  CAS  PubMed  Google Scholar 

  23. Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M, et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol. 2004;43:1090–100.

    Article  CAS  PubMed  Google Scholar 

  24. Jahns R, Boivin V, Siegmund C, Boege F, Lohse MJ, Inselmann G. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol. 1999;34:1545–51.

    Article  CAS  PubMed  Google Scholar 

  25. Bornholz B, Weidtkamp-Peters S, Schmitmeier S, Seidel CA, Herda LR, Felix SB, et al. Impact of human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res. 2013;97:472–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Stork S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152:697–704.

    Article  PubMed  Google Scholar 

  27. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:418–24.

    Article  CAS  PubMed  Google Scholar 

  28. Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, et al. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. J Card Fail. 2009;15:224–32.

    Article  CAS  PubMed  Google Scholar 

  29. Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, et al. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun. 2003;20:345–50.

    Article  CAS  PubMed  Google Scholar 

  30. Wallukat G, Haberland A, Berg S, Schulz A, Freyse EJ, Dahmen C, et al. The first aptamer-apheresis column specifically for clearing blood of beta1-receptor autoantibodies. Circ J. 2012;76:2449–55.

    Article  CAS  PubMed  Google Scholar 

  31. Wallukat G, Muller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med. 2002;347:1806.

    Article  PubMed  Google Scholar 

  32. Sterin-Borda L, Gorelik G, Borda ES. Chagasic IgG binding with cardiac muscarinic cholinergic receptors modifies cholinergic-mediated cellular transmembrane signals. Clin Immunol Immunopathol. 1991;61:387–97.

    Article  CAS  PubMed  Google Scholar 

  33. Wallukat G, Fu HM, Matsui S, Hjalmarson A, Fu ML. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects. Life Sci. 1999;64:465–9.

    Article  CAS  PubMed  Google Scholar 

  34. Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J. 2004;25:1108–15.

    Article  CAS  PubMed  Google Scholar 

  35. Del Corsso C, de Carvalho AC, Martino HF, Varanda WA. Sera from patients with idiopathic dilated cardiomyopathy decrease ICa in cardiomyocytes isolated from rabbits. Am J Physiol Heart Circ Physiol. 2004;287:H1928–36.

    Article  PubMed  Google Scholar 

  36. Zou C, Zhang Z, Zhao W, Li G, Ma G, Yang X, et al. Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation. J Transl Med. 2013;11:7.

    Article  CAS  PubMed  Google Scholar 

  37. Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. 2006;114:1693–702.

    Article  PubMed  Google Scholar 

  38. Miettinen KH, Eriksson S, Magga J, Tuomainen P, Kuusisto J, Vanninen EJ, et al. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail. 2008;14:481–8.

    Article  CAS  PubMed  Google Scholar 

  39. Doesch AO, Mueller S, Nelles M, Konstandin M, Celik S, Frankenstein L, et al. Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy. Basic Res Cardiol. 2011;106:25–35.

    Article  CAS  PubMed  Google Scholar 

  40. Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Hardt S, et al. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy. J Clin Apher. 2009;24:141–9.

    PubMed  Google Scholar 

  41. Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:1153–9.

    Article  CAS  PubMed  Google Scholar 

  42. Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, Wainai Y, et al. Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump in immunized cardiomyopathic rabbits. Int J Cardiol. 2006;112:15–20.

    Article  PubMed  Google Scholar 

  43. Goldman JH, Keeling PJ, Warraich RS, Baig MK, Redwood SR, Dalla Libera L, et al. Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy. Br Heart J. 1995;74:598–603.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Magnusson Y, Marullo S, Hoyer S, Waagstein F, Andersson B, Vahlne A, et al. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1990;86:1658–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–7.

    Article  CAS  PubMed  Google Scholar 

  46. Magnusson Y, Hjalmarson A, Hoebeke J. Beta 1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol. 1996;54:137–41.

    Article  CAS  PubMed  Google Scholar 

  47. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999;99:649–54.

    Article  CAS  PubMed  Google Scholar 

  48. Dandel M, Weng Y, Siniawski H, Potapov E, Drews T, Lehmkuhl HB, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118:S94–105.

    Article  PubMed  Google Scholar 

  49. Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993;91:1964–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Yoshizawa A, Nagai S, Baba Y, Yamada T, Matsui M, Tanaka H, et al. Autoimmunity against M(2)muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype. Eur J Immunol. 2012;42:1152–63.

    Article  CAS  PubMed  Google Scholar 

  51. Shmilovich H, Danon A, Binah O, Roth A, Chen G, Wexler D, et al. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. Int J Cardiol. 2007;117:198–203.

    Article  PubMed  Google Scholar 

  52. Halley CM, Lappe JM, Cotleur AC, Shrestha K, Borowski AG, Pelfrey C, et al. Antiinflammatory autoimmune cellular responses to cardiac troponin I in idiopathic dilated cardiomyopathy. J Card Fail. 2011;17:359–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Dorffel WV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation. 1997;95:1994–7.

    Article  CAS  PubMed  Google Scholar 

  54. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35:1590–8.

    Article  CAS  PubMed  Google Scholar 

  55. Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:385–91.

    Article  CAS  PubMed  Google Scholar 

  56. Knebel F, Bohm M, Staudt A, Borges AC, Tepper M, Jochmann N, et al. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol. 2004;97:517–20.

    Article  PubMed  Google Scholar 

  57. Dorffel WV, Wallukat G, Dorffel Y, Felix SB, Baumann G. Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up. Int J Cardiol. 2004;97:529–34.

    Article  PubMed  Google Scholar 

  58. Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J. 2006;152:712. e1-6.

    Article  PubMed  Google Scholar 

  59. Cooper LT, Belohlavek M, Korinek J, Yoshifuku S, Sengupta PP, Burgstaler EA, et al. A pilot study to assess the use of protein A immunoadsorption for chronic dilated cardiomyopathy. J Clin Apher. 2007;22:210–4.

    Article  PubMed  Google Scholar 

  60. Nagatomo Y, Baba A, Ito H, Naito K, Yoshizawa A, Kurita Y, et al. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J Clin Apher. 2011;26:1–8.

    Article  PubMed  Google Scholar 

  61. Staudt A, Bohm M, Knebel F, Grosse Y, Bischoff C, Hummel A, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation. 2002;106:2448–53.

    Article  CAS  PubMed  Google Scholar 

  62. Schimke I, Muller J, Dandel M, Gremmels HD, Bayer W, Wallukat B, et al. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher. 2005;20:137–42.

    Article  PubMed  Google Scholar 

  63. Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol. 2002;39:646–52.

    Article  CAS  PubMed  Google Scholar 

  64. Staudt A, Staudt Y, Dorr M, Bohm M, Knebel F, Hummel A. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:829–36. This article clearly showed the pathogenic significance of cardio-depressant AAb.

    Article  PubMed  Google Scholar 

  65. Baba A. Autoantigen estimation and simple screening assay against cardiodepressant autoantibodies in patients with dilated cardiomyopathy. Ther Apher Dial. 2008;12:109–16.

    Article  PubMed  Google Scholar 

  66. Baba A, Akaishi M, Shimada M, Monkawa T, Wakabayashi Y, Takahashi M. Complete elimination of cardiodepressant IgG3 autoantibodies by immunoadsorption in patients with severe heart failure. Circ J. 2010;74:1372–8. This article showed the pathogenic significance of cardio-depressant AAb and anti-cardiac AAb belonging to IgG3 subclass in human DCM.

    Article  CAS  PubMed  Google Scholar 

  67. Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A. Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol. 2007;49:1684–92.This article showed the significance of Fc region in "cardio-depressant AAb" mediated pathogenesis in vitro.

  68. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987;166:1351–61.

    Article  CAS  PubMed  Google Scholar 

  69. Warraich RS, Griffiths E, Falconar A, Pabbathi V, Bell C, Angelini G, et al. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. Faseb J. 2006;20:651–60.

    Article  CAS  PubMed  Google Scholar 

  70. Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients. Biochem Biophys Res Commun. 1999;259:255–61.

    Article  CAS  PubMed  Google Scholar 

  71. Warraich RS, Noutsias M, Kazak I, Seeberg B, Dunn MJ, Schultheiss HP, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J. 2002;143:1076–84.

    Article  CAS  PubMed  Google Scholar 

  72. Baba A. Targeted autoantibodies in apheresis treatment against severe heart failure. Jpn J Apher. 2010;29:187–93.

    Google Scholar 

  73. Braun N, Gutenberger S, Erley CM, Risler T. Immunoglobulin and circulating immune complex kinetics during immunoadsorption onto protein A sepharose. Transfus Sci. 1998;19(Suppl):25–31.

    PubMed  Google Scholar 

  74. Staudt A, Dorr M, Staudt Y, Bohm M, Probst M, Empen K. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J. 2005;150:729–36. This article showed the different efficacy of IA by the efficiency of IgG3 AAb removal.

    Article  CAS  PubMed  Google Scholar 

  75. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. Jama. 2000;283:1183–8.

    Article  CAS  PubMed  Google Scholar 

  76. Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundrom B, Arif G, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005;150:263–9.

    Article  CAS  PubMed  Google Scholar 

  77. Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res. 2011;109:986–92.

    Article  CAS  PubMed  Google Scholar 

  78. Liu J, Wang Y, Chen M, Zhao W, Wang X, Wang H, et al. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One. 2014;9:e86770.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632–9.

    Article  CAS  PubMed  Google Scholar 

  81. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap 3rd LC, Xia Y, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation. 2004;110:1612–9.

    Article  CAS  PubMed  Google Scholar 

  82. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension. 2006;48:711–6.

    Article  CAS  PubMed  Google Scholar 

  83. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension. 2008;52:1168–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  84. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14:855–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Chen J, Larsson L, Haugen E, Fedorkova O, Angwald E, Waagstein F, et al. Effects of autoantibodies removed by immunoadsorption from patients with dilated cardiomyopathy on neonatal rat cardiomyocytes. Eur J Heart Fail. 2006;8:460–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Nagatomo received research grant funding from the Myocarditis Foundation. Dr. Tang is supported by a grant from the National Institutes of Health (R01HL103931).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Yuji Nagatomo and W. H. Wilson Tang declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

    Yuji Nagatomo & W. H. Wilson Tang

  2. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA

    W. H. Wilson Tang

Authors
  1. Yuji Nagatomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. H. Wilson Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. H. Wilson Tang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagatomo, Y., Tang, W.H.W. Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence?. Curr Heart Fail Rep 11, 500–508 (2014). https://doi.org/10.1007/s11897-014-0217-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-014-0217-5

Keywords

Search

Navigation